Regorafenib News and Research

RSS
Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

BEAMing technology detects more mutations linked with secondary drug resistance in GIST patients

BEAMing technology detects more mutations linked with secondary drug resistance in GIST patients

Blood test reveals more gene mutations in cancer than traditional tumor biopsy

Blood test reveals more gene mutations in cancer than traditional tumor biopsy

UC Davis scientists find mechanism in metabolized omega-3 fatty acid that helps combat cancer

UC Davis scientists find mechanism in metabolized omega-3 fatty acid that helps combat cancer

Bayer receives FDA approval for Stivarga to treat advanced gastrointestinal stromal tumors

Bayer receives FDA approval for Stivarga to treat advanced gastrointestinal stromal tumors

Regorafenib phase III results strongly support use in GIST

Regorafenib phase III results strongly support use in GIST

Bowel cancer and GIST patients could benefit from novel oral drug

Bowel cancer and GIST patients could benefit from novel oral drug

Regorafenib able to control resistant gastrointestinal stromal tumor

Regorafenib able to control resistant gastrointestinal stromal tumor

Bayer HealthCare receives FDA approval for Stivarga to treat colorectal cancer

Bayer HealthCare receives FDA approval for Stivarga to treat colorectal cancer

Bayer submits regorafenib NDA with FDA for treatment of metastatic and/or unresectable GIST

Bayer submits regorafenib NDA with FDA for treatment of metastatic and/or unresectable GIST

Bayer receives priority review designation from FDA for regorafenib NDA

Bayer receives priority review designation from FDA for regorafenib NDA

Onyx announces data from regorafenib Phase 3 trial on GIST

Onyx announces data from regorafenib Phase 3 trial on GIST

Bayer submits regorafenib NDA with FDA for treatment of mCRC

Bayer submits regorafenib NDA with FDA for treatment of mCRC

Onyx announces results from regorafenib Phase 3 trial on GIST

Onyx announces results from regorafenib Phase 3 trial on GIST

Mayo Clinic experts available to discuss latest colorectal cancer research and treatment

Mayo Clinic experts available to discuss latest colorectal cancer research and treatment

Onyx reports total operating revenue of $237.0M for fourth quarter 2011

Onyx reports total operating revenue of $237.0M for fourth quarter 2011

Experimental drug helps patients with advanced colon cancer

Experimental drug helps patients with advanced colon cancer

New research into treatment, prognosis and early detection of GI cancers

New research into treatment, prognosis and early detection of GI cancers

Regorafenib lengthens lives of patients with metastatic colorectal cancer

Regorafenib lengthens lives of patients with metastatic colorectal cancer